# Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events

> **NCT01675076** · PHASE3 · COMPLETED · sponsor: **Ottawa Heart Institute Research Corporation** · enrollment: 663 (actual)

## Conditions studied

- Hematoma

## Interventions

- **DRUG:** Dabigatran
- **DRUG:** Rivaroxaban
- **DRUG:** Apixaban

## Key facts

- **NCT ID:** NCT01675076
- **Lead sponsor:** Ottawa Heart Institute Research Corporation
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2017-10
- **Final completion:** 2018-05
- **Target enrollment:** 663 (ACTUAL)
- **Last updated:** 2019-10-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01675076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01675076, "Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01675076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*